Dr Goebel’s inaugural lecture on the 27th of November - 'The Autoimmune Etiology of Unexplained Chronic Pain'

Joan Crawford

Joan Crawford

Senior Member (Voting Rights)
Please see below information about Dr Goebel’s inaugural lecture on the 27th of November 6pm – see details below this email. This can be accessed virtually and will be recorded to watch afterwards too. The lecture itself starts at 6pm.

From ilcamsevents: ilcamsevents@liverpool.ac.uk

Dear Joan

Thank you for your email and apologies for the late response.

We have been working on ways to access the above lecture remotely and this can now be viewed on line using the following link:

https://liverpool-ac-uk.zoom.us/j/96922639586?pwd=bWh2Vk1NQmg4clZhWnplS1NMQ1NDdz09
Passcode: 3hKqBk@*

The lecture will also be recorded and a link to this will be available after 27th November which we can also send on to you.

Kind Regards
ILCaMS Events


##

Please do share with colleagues, and your networks.


Warm regards,

Joan


Joan Crawford
Counselling Psychologist
Chronic Pain Management Service (CPMS)
The O’Hanlon Centre, Peasley Cross Hospital, Marshalls Cross Road, St Helens. WA9 3DE
01744 415575
joan.crawford2@merseycare.nhs.uk
www.merseycare.nhs.uk


From: Brenda Hall <b.hall@painrelieffoundation.org.uk>
Sent: 31 October 2023 15:12
To: Brenda Hall <b.hall@painrelieffoundation.org.uk>
Subject: FW: Inaugural Lecture by Professor Andreas Goebel - Mon, 27 Nov 2023 17:30 - 20:30 GMT

Dear All,

Andreas has asked me to share this invitation with you.

Date :- Mon, 27th November

Time :- 2023 17:30 - 20:30 GMT

Venue:- University of Liverpool, Central Teaching Hub, Central Teaching Hub Off Brownlow Hill Liverpool L69 7ZD

Title of Lecture: 'The Autoimmune Etiology of Unexplained Chronic Pain'.

Andreas Goebel was born and raised in Wiesbaden/Germany, trained in Anaesthesia and Pain Medicine in Wuerzburg/Germany, and in the UK (Oxford, UCL), and studied post-trauma immunology at Harvard Medical School, Boston, US.

Appointed Consultant in Pain Medicine at the Liverpool/UK Walton Centre in 2007, the largest UK Pain Management service; University of Liverpool Senior Lecturer in Pain medicine 2008, Reader 2016; promoted to Chair of Pain Medicine 2023; Director of the University’s Pain Research Institute.

Andreas’ research has focused on the role of the adaptive immune system in causing chronic pain. He first proposed in 2005 that ‘unexplained’ chronic pains may be caused by non-destructive, non-inflammatory, ‘functional’ IgG autoantibodies and that passive transfer experimental approaches can be used to investigate this.

In this inaugural lecture, Andreas will describe his recent research results voted 2021 Guardian Top 10 Science Story, which have led to the worldwide first biologics trial in Fibromyalgia Syndrome just completed in England’s North-West.

Refreshments will be available.

5.30pm - 6pm Arrivals - Tea / Coffee / Soft Drinks

6.00pm - 6.45pm Lecture

6.45pm - 8.00pm Drinks / Canapes

To register for this event, please use the Eventbrite link below:

https://www.eventbrite.com/e/inaugural-lecture-by-profe ssor-andreas-goebel-tickets-745036974647?aff=oddtdtcreator


Brenda
Brenda Hall
Admin Assistant
Pain Relief Foundation
Clinical Sciences Centre
University Hospital Aintree
For information regarding our events and courses please visit the links below

Pain Relief Foundation
 
@Joan Crawford,

thanks for posting this. If anyone tries to watch this video and quickly gets bored, I found it advantageous to go to about 14 minutes in and that’s when the actual talk seems to start.

The new information for me was the future activities that he intends to partake in and there was a interesting discussion of the use of plasmaphoresis and a newly developed drug that they are going to clinical trial. The drug is Rozanolixizumab, which was approved by the FDA this year for use in the United States to treat myasthenia gravis. It is interesting/coincidental that another drug that has been prescribed for myasthenia gravis is pyridostigmine…

 
Last edited:
Dr Goebel’s lab is seeking donations "to fund two new therapeutic treatment trials for FMS and the development of prognostic and diagnostic blood tests."

2021 publication: https://www.jci.org/articles/view/144201
Passive transfer of fibromyalgia symptoms from patients to mice

https://painrelieffoundation.org.uk/donate-now-for-new-treatments-for-fibromyalgia/
Donate Now for New Treatments for Fibromyalgia | The Pain Relief Foundation

"The first trial assesses a drug that targets the neonatal Fc receptor complex (FcRn) in order to reduce IgG load. The second looks at Plasma Exchange, which removes IgG from the system. Both are known treatments with a good safety record when used in other immune-related conditions; they have just not been formally tried in FMS."

Anyone got any thoughts on this? Thanks.
@Jonathan Edwards
 
Joan Crawford said:
Anyone got any thoughts on this? Thanks.
@Jonathan Edwards
Click to expand...

Plasma exchange is cumbersome, expensive and never worked very well for most things probably because it has no selectivity. I wouldn't revisit it. The FcRN strategy is newer but not much better I suspect. Reducing IgG load isn't going to do a lot.

But before even considering these things there needs to be decent evidence for some autoantibody role in humans. I haven't seen anything yet. I regularly attend presentations on autoantibodies in rheumatology and nobody is mentioning this stuff either.
 
Jonathan Edwards said:
Plasma exchange is cumbersome, expensive and never worked very well for most things probably because it has no selectivity. I wouldn't revisit it. The FcRN strategy is newer but not much better I suspect. Reducing IgG load isn't going to do a lot.

But before even considering these things there needs to be decent evidence for some autoantibody role in humans. I haven't seen anything yet. I regularly attend presentations on autoantibodies in rheumatology and nobody is mentioning this stuff either.
Click to expand...

Thanks that useful to know.
 
You must log in or register to reply here.
Back
Top Bottom